Business Vision HomeAbout C-TRIBusiness Vision
Two-track growth strategy aiming to boost sales in pharmaceutical sector and new growth engine business
Since its inception in 1998, C-TRI has recorded robust sales in prescription drugs and OTCs based on stable surplus management. To provide a new growth engine, the company has focused on the development of platform technologies in amino acid/peptide (bio) drugs and green energy (ionic liquids) through ceaseless research efforts and aggressive R&D spending, thus emerging as a company equipped with cutting-edge peptide technology. Based on a sizable product portfolio (pharmaceuticals and peptide drugs),

C-TRI is geared to lead the peptide therapeutics market and will continue to challenge for the coming years as a research-oriented biopharmaceutical company that can be recognized at home and abroad.